Neurosafe Kicked off the Clinical Trial for LAVA Liquid Embolic System in China in Nov 2021. The first passed ethics was the First Affiliated Hospital of Zhengzhou University, and the first enrolled case was in the same hospital. Till now, 88 enrolled cases (42 cases in the test group and 46 cases in the control group) were successfully embolized and withdrawn smoothly, and the embolization success rate was 100%. Up to now, 9 cases and 20 SAEs have occurred in the project, and no SAEs related to the experimental devices have occurred.
The Clinical Trial for LAVA Liquid Embolic System will be finished in Nov 2023 and the clinical reports will be completed in June 2024.
During the clinical trial, the surgons’feedback is that LAVA Liquid Embolic System has the same treatment with ONXY, but LAVA Liquid Embolic System is more ecmonic for the patients
